Gibson Dunn Advised Merck On $10 Billion Acquisition Of Verona Pharma

Gibson Dunn Advised Merck on $10 Billion Acquisition of Verona Pharma

Gibson Dunn advised Merck & Co., Inc., one of the world’s largest pharmaceutical companies, on its $10 billion acquisition of Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases. This strategic transaction is expected to strengthen Merck’s innovative pipeline and expand its portfolio of treatments for patients suffering from serious respiratory conditions.

The Gibson Dunn antitrust team advising Merck includes Stephen Weissman (Partner), Michael Perry (Partner), and Tristan Locke (Associate), all based in Washington, D.C. The team is providing comprehensive antitrust counsel to secure regulatory approvals and ensure a smooth closing of this major cross-border acquisition.

Click to know more about Gibson Dunn

If you have a news or deal publication or would like to collaborate on content, columns, or article publications, connect with the Legal Era News Network Team and email us at [email protected] or call us on +91 8879634922.